p.90 抽出テキスト

hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol 2008;123:138–46. https://doi.org/10.1016/j.ijcard.2006.12. 001 303. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–33. https://doi. org/10.1056/NEJM199702203360801 304. Bavendiek U, Grosshennig A, Schwab J, Berliner D, Rieth A, Maier LS, et al. Digitoxin in patients with heart failure and reduced ejection fraction. N Engl J Med 2025;393:1155–65. https://doi.org/10.1056/NEJMoa2415471 305. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 2015;36:1831–8. https://doi.org/10.1093/eurheartj/ehv143 306. Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet 2015; 385:2363–70. https://doi.org/10.1016/S0140-6736(14)61836-5 307. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363–73. https://doi.org/10.1056/NEJMoa1001337 308. Ahmed A, Gambassi G, Weaver MT, Young JB, Wehrmacher WH, Rich MW. Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure. Am J Cardiol 2007;100: 280–4. https://doi.org/10.1016/j.amjcard.2007.02.099 309. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 2021;384:105–16. https://doi.org/10.1056/NEJMoa2025797 310. Hulot JS, Ter Maaten JM, Bayes-Genis A, Halliday BP, Metra M, Moura B, et al. Heart failure improvement, remission, and recovery: a European Journal of Heart Failure expert consensus document. Eur J Heart Fail 2025; 27:1807–19. https://doi.org/10.1002/ejhf.3732 311. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022;400:1938–52. https://doi.org/10.1016/ S0140-6736(22)02076-1 312. Beldhuis IE, Lam CSP, Testani JM, Voors AA, Van Spall HGC, Ter Maaten JM, et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation 2022;145:693–712. https://doi.org/10.1161/CIRCULATIONAHA.121. 052792 313. Cannata A, McDonagh TA. Heart failure with preserved ejection fraction. N Engl J Med 2025;392:173–84. https://doi.org/10.1056/NEJMcp2305181 314. Anker SD, Usman MS, Anker MS, Butler J, Bohm M, Abraham WT, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail 2023;25:936–55. https://doi.org/10.1002/ ejhf.2894 315. Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069–84. https://doi.org/10.1056/ NEJMoa2306963 316. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024;390:1394–407. https://doi.org/10.1056/ NEJMoa2313917 317. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427–37. https://doi.org/10.1056/NEJMoa2410027 318. McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, et al. Effects of sacubitril–valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation 2020;141:338–51. https://doi.org/10.1161/ CIRCULATIONAHA.119.044491 319. Solomon SD, Vaduganathan M, B LC, Packer M, Zile M, Swedberg K, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020;141:352–61. https://doi.org/10.1161/CIRCULATIONAHA. 119.044586 320. Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT. Beta-blockers and inhibitors of the renin–angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev 2018;6: CD012721. https://doi.org/10.1002/14651858.CD012721.pub2 321. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393:61–73. https://doi.org/10.1016/S0140- 6736(18)32484-X 322. Cheng L, Hammersley D, Ragavan A, Javed S, Mukhopadhyay S, Gregson J, et al. Long-term follow-up of the TRED-HF trial: implications for therapy in patients with dilated cardiomyopathy and heart failure remission. Eur J Heart Fail 2025;27:113–23. https://doi.org/10.1002/ejhf.3475 323. Belfort DSP, Bocchi EA, Cafezeiro CRF, Wanderley MRB Jr, Salemi VMC, Rocon C, et al. Carvedilol as single therapy for heart failure with improved ejection fraction: a randomized clinical trial (CATHEDRAL-HF). JACC Heart Fail 2025;13:1041–44. https://doi.org/10.1016/j.jchf.2025.02.022 324. Segan L, Kistler PM, Nanayakkara S, Taylor A, Hare J, Costello B, et al. Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial. Eur Heart J 2025;47:250–62. https://doi.org/10.1093/eurheartj/ehaf563 325. Nijst P, Martens P, Dauw J, Tang WHW, Bertrand PB, Penders J, et al. Withdrawal of neurohumoral blockade after cardiac resynchronization therapy. J Am Coll Cardiol 2020;75:1426–38. https://doi.org/10.1016/j.jacc. 2020.01.040 326. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117–28. https://doi.org/10.1056/NEJMoa2030183 327. Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA 2023;329:214–23. https://doi.org/10.1001/jama.2022. 23924 328. Faselis C, Arundel C, Patel S, Lam PH, Gottlieb SS, Zile MR, et al. Loop diuretic prescription and 30-day outcomes in older patients with heart failure. J Am Coll Cardiol 2020;76:669–79. https://doi.org/10.1016/j.jacc.2020.06.022 329. Rohde LE, Rover MM, Figueiredo Neto JA, Danzmann LC, Bertoldi EG, Simoes MV, et al. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a doubleblind, multicentre, randomized trial. Eur Heart J 2019;40:3605–12. https:// doi.org/10.1093/eurheartj/ehz554 330. Lund LH, Benson L, Dahlstrom U, Edner M, Friberg L. Association between use of beta-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA 2014;312:2008–18. https://doi.org/10. 1001/jama.2014.15241 331. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174–83. https://doi.org/10.1016/S0140-6736(08)61242-8 332. Morrow DA, Velazquez EJ, Desai AS, DeVore AD, Lepage S, Park JG, et al. Sacubitril/valsartan in patients hospitalized with decompensated heart failure. J Am Coll Cardiol 2024;83:1123–32. https://doi.org/10.1016/j.jacc. 2024.01.027 333. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin–angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 2012;308:2108–17. https://doi. org/10.1001/jama.2012.14785 334. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456–67. https://doi.org/10.1056/NEJMoa0805450 335. Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol 2023;82:1–12. https://doi.org/10.1016/j.jacc.2023.04.019 336. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Ostergren J, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail 2014;16:33–40. https://doi.org/10.1002/ejhf.29 337. Zafeiropoulos S, Farmakis IT, Milioglou I, Doundoulakis I, Gorodeski EZ, Konstantinides SV, et al. Pharmacological treatments in heart failure with mildly reduced and preserved ejection fraction: systematic review and network meta-analysis. JACC Heart Fail 2024;12:616–27. https://doi.org/10. 1016/j.jchf.2023.07.014 338. Cleland JG, Chattopadhyay S, Khand A, Houghton T, Kaye GC. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev 2002;7:229–42. https://doi.org/10.1023/a:1020024122726 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026